Celsion Falls Most Ever After Liver Cancer Drug Fails
Celsion fell 81 percent to $1.51 at the close in New York, the biggest single-day decline since the shares began trading in April 1994. The stock had almost quadrupled in the 12 months through yesterday.
The cancer treatment, called ThermoDox, didn’t meet the study’s primary goal of slowing liver tumor growth in the final stage of testing usually required to get regulatory approval, the Lawrenceville, New Jersey-based company said today in a statement. Celsion said it has about $27 million in cash and investments that will help it evaluate future development plans.
To contact the reporter on this story: Shannon Pettypiece in New York at email@example.com
To contact the editor responsible for this story: Reg Gale at firstname.lastname@example.org